| [1] | GBD 2023 Chronic Kidney Disease Collaborators. (2025). Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: A systematic analysis for the Global Burden of Disease Study 2023. Lancet 406:2461-2482. DOI:10.1016/S0140-6736(25)00637-4 |
| [2] | Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. (2024). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 105:S1-S155. DOI:10.1016/j.kint.2024.03.018 |
| [3] | Fiseha T., Ekong N.E. and Osborne N.J. (2024). Chronic kidney disease of unknown aetiology in Africa: A review of the literature. Nephrology 29:177−187. DOI:10.1111/nep.14288 |
| [4] | Oguejiofor F., Kiggundu D.S., Bello A.K., et al. (2021). International Society of Nephrology Global Kidney Health Atlas: Structures, organization, and services for the management of kidney failure in Africa. Kidney Int. Suppl. 11:e11−e23. DOI:10.1016/j.kisu.2021.01.009 |
| [5] | Heerspink H.J.L., Stefánsson B.V., Correa-Rotter R., et al. (2020). Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383:1436−1446. DOI:10.1056/NEJMoa2024816 |
| Wang C., Long T. and Chen A. (2026). The silent epidemic and pronounced disparities: A global review of the chronic kidney disease burden. The Innovation Medicine 4:100224. https://doi.org/10.59717/j.xinn-med.2026.100224 |
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
The global CKD burden: a silent epidemic, a pronounced disparity, a call for integrated action.